Personalis Inc. (04X)
XDUS 
Summary
04X Chart
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap.
Personalis Q1 Earnings Call Highlights
Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue.
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis Inc. (04X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Personalis Inc. ever had a stock split?
Personalis Inc. Profile
| Professional Services Industry | Industrials Sector | Mr. Christopher M. Hall CEO | XDUS Exchange | US71535D1063 ISIN |
| US Country | 259 Employees | - Last Dividend | - Last Split | 20 Jun 2019 IPO Date |
Overview
Personalis, Inc. is a biotechnology firm, established in 2011 with its headquarters in Fremont, California, that specializes in the development and marketing of innovative cancer genomic tests and analytics. The company serves a broad international market, including regions such as the United States, Europe, and the Asia-Pacific. Personalis caters to the needs of pharmaceutical companies for translational research and biomarker discovery, aiding the development of personalized cancer therapies. Moreover, it provides sophisticated tests employed by physicians to identify cancer recurrence, monitor the evolution of the disease, and discover vital information for choosing appropriate therapy options. Its clientele encompasses pharmaceutical and biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and individual patients.
Products and Services
- NeXT Personal
- ImmunoID NeXT
- NeXT Personal Dx
- NeXT Dx
- Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)
This is a tumor-informed liquid biopsy test designed for the detection of minimal residual disease (MRD) and the recurrence of cancer. It enables personalized monitoring and treatment options by providing a deep insight into the molecular signature of an individual's cancer.
A tissue-based comprehensive test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data. Through advanced analytics, it offers a multi-dimensional view of the tumor and its microenvironment from a single sample, facilitating the development of targeted cancer therapies and immunotherapies.
Similar to NeXT Personal, this test offers tumor-informed liquid biopsy capabilities for the detection of MRD and cancer recurrence, specifically designed with a diagnostic focus to aid clinicians in the personalized treatment of cancer patients.
A comprehensive tumor profiling test that unlocks insights into the entire exome (DNA) and transcriptome (RNA) of a cancer patient. By providing matched tumor-normal analysis, it leverages detailed genomic information to better understand the disease and guide treatment options.
Personalis offers WES of cancer tissue and matched blood samples, and WGS on human samples for a variety of purposes including diagnostic tool development, research projects, and population sequencing initiatives. These services are complemented by the company’s sequencing and data analysis capabilities, supporting the broader research and medical community in uncovering new insights into cancer genomics.
